Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
This study will be an open-label, randomized, multi-center, 2-way crossover Pharmacokinetic
PK evaluation of a single inhaled dose of CVT-301 84 mg and a single oral dose of
carbidopa/levodopa CD/LD 25 mg/100 mg (Sinemet®) under fed conditions in Parkinson's Disease
(PD) patients who regularly take CD/LD.
Phase:
Phase 1
Details
Lead Sponsor:
Acorda Therapeutics
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa